Re-Treatment With 177Lu-DOTATATE in Patients With Neuroendocrine Tumors: Multicenter Real-World Experience

被引：0
|
作者：
Navalkissoor, S. [1 ]
Essler, M. [2 ]
Caplin, M. [1 ]
Van Der Zwan, W. [3 ]
Wicharz, M. [2 ]
De Herder, W. [3 ]
Broberg, P. [4 ]
Krenning, E. [3 ]
机构：
[1] Royal Free London NHS Fdn Trust, London, England
[2] Univ Klinikum Bonn, Bonn, Germany
[3] Erasmus MC, Rotterdam, Netherlands
[4] Adv Accelerator Applicat, Geneva, Switzerland
来源：
PANCREAS | 2021年 / 50卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
C-27
引用
收藏
页码：453 / 453
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF RE-TREATMENT WITH 177LU-DOTATATE VERSUS NO RE-TREATMENT WITH 177LU-DOTATATE IN PATIENTS WITH PROGRESSIVE MIDGUT NEUROENDOCRINE TUMORS
    Leeuwenkamp, O.
    Mahon, R.
    Singh, M. K.
    Khare, A.
    VALUE IN HEALTH, 2020, 23 : S446 - S446
  • [2] 177Lu-DOTATATE Treatment In Unresectable Neuroendocrine Tumors: Our Experience
    Agudelo, M.
    Bello-Arques, P.
    Olivan-Sasot, P.
    Prado-Wohlwend, S.
    Sanchez-Vano, R.
    Yepes-Agudelo, A.
    Martinez-Sanchis, B.
    Bernal-Vergara, J.
    Figueroa-Ardila, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S596 - S597
  • [3] 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
    Das, Satya
    Al-Toubah, Taymeyah
    El-Haddad, Ghassan
    Strosberg, Jonathan
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (11) : 1023 - 1031
  • [4] 177Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community setting
    Sassic, Jessica
    Farasat, Sadaf
    Hermel, David
    Sigal, Darren
    Xavier, Marin Feldman
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] 177Lu-DOTATATE/DOTATOC Re-Treatment in Patients With Progressive Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
    Strosberg, J.
    Leeuwenkamp, O.
    Siddiqui, M. K.
    PANCREAS, 2021, 50 (03) : 452 - 452
  • [6] 177Lu-Dotatate for Midgut Neuroendocrine Tumors
    Ozdemir, Nuriye Y.
    Arslan, Suheyla A.
    Sendur, Mehmet A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14): : 1391 - 1391
  • [7] Real-world efficacy and safety of re-treatment with [177Lu]Lu-DOTA-TATE in patients with neuroendocrine tumors (NETs)
    Velazquez, F.
    Garcia-Burillo, A.
    Pubul Nunez, V.
    Asadurova, S.
    Hernando Cubero, J.
    Martinez-Lago, N.
    Calatayud Cubes, A.
    Anido Herranz, U.
    Garcia-Alvarez, A.
    De Matias Leralta, J.
    Echeverri Diaz, J.
    Suils Ramon, J.
    Calvino, N.
    Canela Coll, T.
    Marusso Fizzani, M.
    Hernandez Cristancho, O.
    Gamez Cenzano, C.
    Capdevila, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S664 - S665
  • [8] Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A multicenter study
    Mitjavila Casanovas, M.
    Pubul, V.
    Bello, P.
    Miguel, B.
    Cano, J.
    Balaguer, D.
    Garcia-Burillo, A.
    Marino Mendez, A.
    Rodeno, E.
    Custodio, A.
    Pineiro, A.
    Garcia-Canamaque, L.
    Castellon, M.
    Orduna, M.
    Carmona-Bayonas, A.
    Jimenez-Fonseca, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S103 - S104
  • [9] Efficacy of Everolimus Combined with 177Lu-Dotatate in the Treatment of Neuroendocrine Tumors
    Aljubran, Ali
    Badran, Ahmed
    Alrowaily, Mohamed
    Raef, Hussein
    Alzahrani, Ahmed M.
    Almuhaideb, Ahmed
    Almanea, Hadeel
    El-Dali, Abdelmoneim
    Tuli, Mahmoud
    Bazarbashi, Shouki
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2024, 39 (02) : 164 - 168
  • [10] Effectiveness and Safety of Retreatment with 177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States
    Delpassand, Ebrahim S.
    Yazdi, Soheil M.
    Ghantoji, Shashank
    Nakasato, Antonio
    Strickland, Corinne
    Nunez, Rodolfo
    Shafie, Afshin
    Cork, Susan
    Byrne, Clare
    Tang, Jackson
    Patel, Jeetvan
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (05) : 746 - 752
12345